<?xml version="1.0" encoding="UTF-8"?>
<ref id="b17-1031654">
 <label>17.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yee</surname>
    <given-names>AL</given-names>
   </name>
   <name>
    <surname>Zeng</surname>
    <given-names>Z</given-names>
   </name>
   <name>
    <surname>Konople</surname>
   </name>
  </person-group>
  <article-title>Phase I/II study of the mammalian target or rapamycin inhibitor everolimus (RAD001) inn patients with relapsed or refractory hematologic malignancies</article-title>. 
  <source>Clin Cancer Res</source>. 
  <year>2006</year>;
  <volume>12</volume>(
  <issue>17</issue>): 
  <fpage>5165</fpage>â€“
  <lpage>5173</lpage>.
  <pub-id pub-id-type="pmid">16951235</pub-id>
 </mixed-citation>
</ref>
